Indobufen (K 3920), a new inhibitor of platelet aggregation: effect of food on bioavailability, pharmacokinetic and pharmacodynamic study during repeated oral administration to man.
The effect of food on bioavailability of indobufen tablets was investigated in 6 healthy volunteers. Subsequently, the same subjects took 100 mg b.i.d. for 7 days. Plasma levels and urinary excretion of indobufen were determined by GLC. Platelet aggregation induced by several concentrations of adrenaline was determined turbidimetrically at various times after the first and last doses. The absorption of indobufen tablets was not substantially impaired by the presence of food in the GI tract, although peak plasma levels and AUCs were slightly reduced after food. Pharmacokinetic analysis of plasma and urinary levels of indobufen did not indicate any change in drug disposition after repeated dosing. Adrenaline-induced platelet aggregation was markedly inhibited for up to 12 h after the first dose  and the intensity and duration of this effect did not change after repeated administration. A twice-daily dosing appears suitable for clinical trials.
D000328:Adult; D001682:Biological Availability; D004837:Epinephrine / Q000494:pharmacology; D005215:Fasting; D005502:Food; D006801:Humans; D007700:Kinetics; D008297:Male; D010654:Phenylbutyrates / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D010974:Platelet Aggregation / Q000187:drug effects*
D010654:Phenylbutyrates; D004837:Epinephrine